- Home
- DSGN vs THRD Comparison
DSGN vs THRD Comparison
Compare DSGN & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- THRD
- Stock Information
- Founded
- DSGN 2017
- THRD 2019
- Country
- DSGN United States
- THRD United States
- Employees
- DSGN N/A
- THRD N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- THRD Health Care
- Exchange
- DSGN Nasdaq
- THRD Nasdaq
- Market Cap
- DSGN 348.2M
- THRD 335.2M
- IPO Year
- DSGN 2021
- THRD 2022
- Fundamental
- Price
- DSGN $4.87
- THRD $6.00
- Analyst Decision
- DSGN Hold
- THRD Strong Buy
- Analyst Count
- DSGN 3
- THRD 3
- Target Price
- DSGN $7.00
- THRD $20.33
- AVG Volume (30 Days)
- DSGN 220.6K
- THRD 248.2K
- Earning Date
- DSGN 03-18-2025
- THRD 11-07-2024
- Dividend Yield
- DSGN N/A
- THRD N/A
- EPS Growth
- DSGN N/A
- THRD N/A
- EPS
- DSGN N/A
- THRD N/A
- Revenue
- DSGN N/A
- THRD N/A
- Revenue This Year
- DSGN N/A
- THRD N/A
- Revenue Next Year
- DSGN N/A
- THRD N/A
- P/E Ratio
- DSGN N/A
- THRD N/A
- Revenue Growth
- DSGN N/A
- THRD N/A
- 52 Week Low
- DSGN $2.25
- THRD $5.60
- 52 Week High
- DSGN $7.77
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- DSGN 42.19
- THRD 23.75
- Support Level
- DSGN $3.71
- THRD $5.60
- Resistance Level
- DSGN $6.81
- THRD $11.78
- Average True Range (ATR)
- DSGN 0.50
- THRD 0.89
- MACD
- DSGN -0.10
- THRD -0.43
- Stochastic Oscillator
- DSGN 37.42
- THRD 6.50
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.